EMC was part of the international H2020 project "RELENT"
New Products:
Anti-peptide cellular immune response with adjuvant XS15
Our latest publications:
H.-G. Rammensee, K.-H. Wiesmüller, P. A. Chandran et al. (2019) A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. J. immunotherapy cancer 7, 307 doi:10.1186/s40425-019-0796-5.
H.-G. Rammensee, C. Gouttefangeas, C. Heidu et al. (2021) Designing a SARS-CoV-2 T-cell-Inducing vaccine for high-risk patient groups. Vaccines 9, 428. https://doi.org/10.3390/vaccines9050428.
J. Hansen, K. Kolbe, I.R. K önig, R. Scherließ, M. Hellfritzsch, S. Malm, S. Müller-Loennies, J. Zallet, D. Hillemann, K.-H. Wiesmüller, C. Herzmann, J. Brandenburg, N. Reiling (2022) Lipobiotin-capture magnetic bead assay for isolation, enrichment and detection of Mycobacterium tuberculosis from saliva. PLoS One. Jul 15;17(7):e0265554. https://doi.org/10.1371/journal.pone.0265554
Download our lists of selected publications in the field of: